Active substanceMeldoneyMeldoney
Similar drugsTo uncover
  • Angiocarcinoma
    solution for injections 
  • Vazomag
    solution for injections 
    Olainfarm, AO     Latvia
  • Idrinol®
    solution in / in d / eye 
  • Idrinol®
    capsules inwards 
    Olainfarm, AO     Latvia
  • Cardionate®
    solution for injections 
    NIZHFARM, JSC     Russia
  • Cardionate®
    capsules inwards 
    NIZHFARM, JSC     Russia
  • Cardionate®
    capsules inwards 
    MAKIZ-PHARMA, LLC     Russia
  • Meldoney
    solution in / in d / eye w / m 
    ELLARA, LTD.     Russia
  • Meldoney
    capsules inwards 
  • Meldoney
    solution for injections 
    BIOCHEMIST, OJSC     Russia
  • Meldoney
    solution for injections 
  • Meldoney
    solution for injections 
    ATOLL, LLC     Russia
  • Meldoney
    solution for injections 
    BIOSINTEZ, PAO     Russia
  • Meldonius Organica
    solution for injections 
    ORGANICS, JSC     Russia
  • Meldonium-Binergia
    solution in / in d / eye 
    BINERGIYA, CJSC     Russia
  • Meldonij DECO
    solution for injections 
    Company DEKO, LLC     Russia
  • Meldonius-SOLOFARM
    solution for injections 
    GROTEKS, LLC     Russia
  • Meldonius-Eskom
    solution for injections 
    ESKOM NPK, OAO     Russia
  • Melfor®
    solution for injections 
    AVISTA, LLC     Russia
  • Melfor®
    capsules inwards 
       
  • MILDRONATE®
    capsules inwards 
    GRINDEX, JSC     Latvia
  • MILDRONATE®
    capsules inwards 
    GRINDEX, JSC     Latvia
  • MILDRONATE®
    solution w / m in / in d / eye 
    GRINDEX, JSC     Latvia
  • Dosage form: & nbspsolution for intravenous and parabulbar injection
    Composition:

    1 ml of the solution contains:

    active substance; meldonia dihydrate without adsorbed moisture - 100 mg (in terms of meldonium anhydrous - 80.21 mg);

    Excipients: water for injections.

    Description:

    Transparent colorless liquid.

    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    C.01.E.B.22   Meldoney

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Meldonium is a structural analogue of gamma-butyrobetaine, a substance that is present in every human cell. Meldoney suppresses gamma-bugiro-betaine hydroxygenase, reduces synthesis of carnitine and transport of long-chain fatty acids through cell walls, prevents accumulation of activated forms of unoxidized fatty acids in cells - acylcarnitine and acylcoenzyme derivatives. In conditions of ischemia, it restores the equilibrium of oxygen delivery and consumption in cells, adenosine triphosphate (ATP).Simultaneously, it activates glycolysis, which proceeds without additional consumption of oxygen. As a result of a decrease in the concentration of carnitine, gamma-butyrobetaine, which has vasodilating properties, is synthesized intensively. The mechanism of action determines the variety of its pharmacological effects: increase in efficiency, decrease in symptoms of mental and physical overstrain, activation of tissue and humoral immunity, cardioprotective action. In case of acute ischemic damage, the myocardium slows the formation of the necrosis zone, shortens the rehabilitation period. With heart failure improves myocardial contractility, increases exercise tolerance, reduces the incidence of angina attacks. In acute and chronic ischemic impairment of cerebral circulation improves blood circulation in the source of ischemia. Effective in the case of vascular pathology of the fundus. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during the period of withdrawal.

    Pharmacokinetics:

    The maximum concentration in the blood plasma is achieved immediately after administration.Metabolized in the body with the formation of two major metabolites, which are excreted by the kidneys. The half-life is 3-6 hours.

    Indications:

    - in the complex therapy of coronary heart disease (angina pectoris, myocardial infarction); chronic heart failure, dyshormonal cardiomyopathy;

    - in the complex therapy of acute cerebral circulation disorders (ischemic stroke, cerebrovascular insufficiency);

    - reduced working capacity; physical overstrain (including athletes);

    - syndrome of withdrawal from chronic alcoholism (in combination with specific therapy);

    - hemophthalmia and hemorrhages in the retina of the eye of various etiologies, thrombosis of the central vein of the retina and its branches, retinopathy of various etiologies (diabetic, hypertonic).

    Contraindications:

    - hypersensitivity to the components of the drug;

    - increased intracranial pressure (with violation of venous outflow and intracranial tumors);

    - age to 18 years (efficacy and safety not established).

    Carefully:Diseases of the liver and / or kidney.
    Pregnancy and lactation:

    The safety of the drug during pregnancy is not proven.To avoid possible adverse effects on the fetus, do not prescribe the drug during pregnancy.

    It is not known whether the drug is excreted in breast milk. If it is necessary to use Idrinol® during lactation, breastfeeding should be discontinued.

    Dosing and Administration:

    In connection with the possibility of developing an exciting effect, the drug is recommended for use in the first half of the day.

    Cardiovascular diseases

    In the complex therapy - intravenously 500 mg - 1.0 g (5-10 ml solution for intravenous and parabulbar injection 100 mg / ml), applying the entire dose at once or dividing it into 2 injections. The course of treatment is 10-14 days.

    Repeated courses (usually 2-3 times a year) - on the recommendation of a doctor.

    Disorders of cerebral circulation

    In the acute phase of cerebral circulation disorders, 500 mg (5 ml of solution for intravenous and parabulbar injection of 100 mg / ml) are administered intravenously once a day for 10 days.

    Reduced performance, physical overexertion (including athletes)

    For mental and physical exertion (including athletes), 500 mg (5 ml solution for intravenous and parabulbar injection 100 mg / ml) are administered once a day. The course of treatment is 10-14 days.

    The syndrome of withdrawal from chronic alcoholism (in combination with specific therapy)

    Abstinence syndrome is used intravenously, 500 mg (5 ml solution for intravenous and parabulbar injection 100 mg / ml) 2 times a day. The course of treatment is 10-14 days.

    Ophthalmology (hemophthalmia and hemorrhages in the retina of the eye of various etiologies, thrombosis of the central vein of the retina and its branches, retinopathy of various etiologies (diabetic, hypertonic).

    The drug is administered parabulbar by 50 mg (0.5 ml solution for intravenous and parabulbar injection 100 mg / ml) for 10 days, including as part of a combination therapy.

    Side effects:

    From the cardiovascular system: rarely - tachycardia, a decrease or increase in blood pressure.

    From the central nervous system: rarely - psychomotor agitation.

    From the digestive system: rarely - dyspeptic disorders.

    Allergic reactions: rarely - skin itching, rash, hyperemia of the skin, angioedema; very rarely - eosinophilia.

    Other: very rarely - general weakness.

    Overdose:

    Symptoms: lowering blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.

    Treatment: symptomatic.

    Interaction:

    You can combine with antianginal drugs, anticoagulants, antiaggregants, antiarrhythmics, diuretics, bronchodilators.

    Strengthens the action of cardiac glycosides.

    In view of the possible development of moderate tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-adrenoblockers, hypotensive drugs and peripheral vasodilators.

    Special instructions:

    Idrinol® is not a first-line drug in acute coronary syndrome.

    Effect on the ability to drive transp. cf. and fur:

    Data on the adverse effects of the preparation Idrinol® on the rate of psychomotor reactions are not available.

    Form release / dosage:

    Solution for intravenous and parabulbar injection 100 mg / ml.

    Packaging:

    5 ml per ampoule of colorless glass.

    5 ampoules per contour cell pack. 1 or 2 contour packs with instructions for use in a pack of cardboard.

    Storage conditions:

    List B. At a temperature of no higher than 25 ° C. Do not freeze.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-000864/10
    Date of registration:10.02.2010 / 13.08.2010
    The owner of the registration certificate:FarmSirma Soteks, ZAO FarmSirma Soteks, ZAO Russia
    Manufacturer: & nbsp
    Information update date: & nbsp17.03.2016
    Illustrated instructions
      Instructions
      Up